Preclinical studies have shown that anlotinib induces hepatoma cell apoptosis by activating the Erk and Akt pathways28; targets the GINS1 gene and consequently regulates synovial sarcoma cell proliferation29; and blocks the MET pathway, thus inhibiting osteosarcoma angiogenesis30. This evidence concerns the gene MET and osteosarcoma.